Adverse events and association with age, sex and immunological parameters of Q fever vaccination in patients at risk for chronic Q fever in the Netherlands 2011

Schoffelen, Teske; Wong, Albert; Rümke, H. C.; Netea, Mihai G.; Timen, Aura; Deuren, Marcel van; Bondt, Patricia E. Vermeer-de

doi:10.1016/j.vaccine.2014.09.061

Cited by 20 publications

(31 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epidemiological studies have shown that Q fever symptoms are more frequent in men than in women (male/female ratio, 2.5), while both are similarly exposed to this pathogen, as evidenced by similar seroprevalence rates (304,305). Recently, the follow-up of patients vaccinated during the Q fever outbreak in the Netherlands revealed higher rates of adverse effects in women than in men (306). The use of murine models of infection revealed the role of sex hormones in the predisposition for infection in men.…”

Section: Role Of the Hostmentioning

confidence: 99%

“…The immunity of adults to C. burnetii accounts for the adult response to vaccine. During the vaccination campaign with Q-vax vaccine in the Netherlands, the best cellular and humoral responses to the antigen as well as protection against the infection were reported in young adults, who also suffered most frequently from local adverse effects (306).…”

Section: Role Of the Hostmentioning

confidence: 99%

See 1 more Smart Citation

From Q Fever to Coxiella burnetii Infection: a Paradigm Change

et al. 2017

View full text Add to dashboard Cite

Coxiella burnetii is the agent of Q fever, or "query fever," a zoonosis first described in Australia in 1937. Since this first description, knowledge about this pathogen and its associated infections has increased dramatically. We review here all the progress made over the last 20 years on this topic. C. burnetii is classically a strict intracellular, Gram-negative bacterium. However, a major step in the characterization of this pathogen was achieved by the establishment of its axenic culture. C. burnetii infects a wide range of animals, from arthropods to humans. The genetic determinants of virulence are now better known, thanks to the achievement of determining the genome sequences of several strains of this species and comparative genomic analyses. Q fever can be found worldwide, but the epidemiological features of this disease vary according to the geographic area considered, including situations where it is endemic or hyperendemic, and the occurrence of large epidemic outbreaks. In recent years, a major breakthrough in the understanding of the natural history of human infection with C. burnetii was the breaking of the old dichotomy between "acute" and "chronic" Q fever. The clinical presentation of C. burnetii infection depends on both the virulence of the infecting C. burnetii strain and specific risks factors in the infected patient. Moreover, no persistent infection can exist without a focus of infection. This paradigm change should allow better diagnosis and management of primary infection and long-term complications in patients with C. burnetii infection.

show abstract

Section: Role Of the Hostmentioning

confidence: 99%

Section: Role Of the Hostmentioning

confidence: 99%

From Q Fever to Coxiella burnetii Infection: a Paradigm Change

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A similar result was found in 2 other studies on tolerability of influenza vaccination and in a study on tolerability of Q-fever, all showing that the odds of AEs decrease with increasing age. 8,10,11 This decreasing risk for AEs with increasing age may be caused by immunosenescence and/or comorbidity or medication. 12 Furthermore, the sex dependency of AEs we found is also found in the Q-fever study 11 and similar to the findings of Harmark et al 8 Several studies comparing MF59 adjuvanted vaccines with non-adjuvanted vaccines, have found that adjuvanted vaccines resulted in slightly more AEs 2,13 as is also known for other adjuvants.…”

Section: Discussionmentioning

confidence: 99%

Tolerability of 2 doses of pandemic influenza vaccine (Focetria®) and of a prior dose of seasonal 2009-2010 influenza vaccination in the Netherlands

Maas

Godefrooij

Bondt

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

In the Netherlands, people indicated for seasonal influenza vaccination are divided in 3 risk groups, i.e. those less than 60 y (y) with comorbidity and those 60 y and over with and without comorbidity. Those risk groups were also eligible for pandemic vaccination during the 2009 influenza A(H1N1) pandemic. We assessed tolerability of seasonal influenza vaccination and 2 doses of pandemic influenza A(H1N1) vaccine, adjuvanted with MF-59, administered 2 and 5 weeks after seasonal 2009-2010 vaccination among adults. Vaccinees were asked to return questionnaires on local and systemic adverse events (AEs) after each of 3 consecutive vaccinations given at the office of their General Practitioner. Sex- and risk group-specific AE-frequencies were calculated. Generalized Linear Mixed Model with seasonal vaccination as reference was used to calculate odds ratios (ORs) for AEs of the 2 pandemic doses. 5553 questionnaires (3251 vaccinees) were returned. Vaccinees reported any local AE after seasonal vaccination and both pandemic doses in 34%, 23%, and 18%, respectively. These percentages were 29%, 25%, and 16% for any systemic AE. Men reported fewer local and systemic AEs then women (p<0.0001). The risk of local (OR range 0.34-0.63) and systemic (OR range 0.39-0.99) AEs (overall, stratified by risk group and by sex) was lower after both pandemic doses compared to seasonal vaccination. This decreased risk was more pronounced after the second pandemic dose than after the first. Therefore, we conclude that MF59-adjuvanted pandemic vaccine given after seasonal vaccination was well tolerated.

show abstract

“…For example, when developing new vaccines, antigens that might enhance the susceptibility of the host to the infection have to be avoided (13). Likewise, a vaccine has to be tested for adverse effects among already infected individuals, such as what has been reported for the Q-fever vaccine (14,15). Another example is the role of the sand fly and how it may affect the immune response in humans.…”

Section: A Vaccine Could Workmentioning

confidence: 99%